SCHEMBL26537124

SCHEMBL26537124

O=S(=O)(Nc1cc(Cl)ccc1OC(F)(F)F)c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.62
FBP1 P09467 1/20 0.57
CCR9 P51686 4/20 0.55
ALDH1A1 P00352 3/20 0.53
FFAR4 Q5NUL3 2/20 0.53
TP53 P04637 2/20 0.53
S100A9 P06702 1/20 0.50
MAPK1 P28482 2/20 0.49
AVPR2 P30518 1/20 0.48
GPR27 Q9NS67 1/20 0.48
CCR2 P41597 4/20 0.48
CCR1 P32246 1/20 0.48
CCR5 P51681 1/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
HSD17B10 Q99714 2/20 0.48
GAA P10253 1/20 0.48
MAPT P10636 1/20 0.48
HTT P42858 1/20 0.48
SCN3A Q9NY46 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26537032 0.91 LMNA (0.77) LMNAFBP1CCR9ALDH1A1FFAR4
SCHEMBL26537047 0.87 LMNA (0.57) LMNAFBP1CCR9ALDH1A1FFAR4
SCHEMBL26536592 0.86 LMNA (0.66) LMNAFBP1CCR9ALDH1A1FFAR4
SCHEMBL26537109 0.86 FFAR4 (0.56) LMNAFBP1CCR9FFAR4CCR2
SCHEMBL26537094 0.85 SLC22A12 (0.57) LMNAFBP1CCR9ALDH1A1FFAR4
SCHEMBL26537147 0.83 CCR9 (0.53) LMNAFBP1CCR9ALDH1A1FFAR4
SCHEMBL7570765 0.79 CES1 (0.67) FBP1ALDH1A1FFAR4TP53MAPT
SCHEMBL14458175 0.77 ALOX15 (0.64) FBP1CCR9ALDH1A1FFAR4AVPR2
SCHEMBL29087421 0.77 KMT2A (0.64) FBP1CCR9FFAR4MEN1KMT2A
SCHEMBL7591561 0.76 FFAR4 (0.64) LMNAFBP1CCR9ALDH1A1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322715-A1 BROAD SPECTRUM ANTI-CANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322715-A1 BROAD SPECTRUM ANTI-CANCER COMPOUNDS YTHDF1, YTHDF3, YTHDF2 LMNA 3852/4885FBP1 2982/4885CCR9 2746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.